Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 8/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ENPP1 | P22413 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26604602 | 0.89 | PDE3A (0.43) | PDE4APDE4BPDE4CPDE4DPDE3A | |
| SCHEMBL6584103 | 0.84 | PDE4B (0.47) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL14826495 | 0.84 | ADORA2A (0.42) | TSHRGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL31321997 | 0.82 | CTSL (0.54) | PDE4APDE4BPDE4CPDE4DPDE3A | |
| SCHEMBL24000490 | 0.80 | GRIN2D (0.43) | KDM4EALDH1A1TSHRGRIN2DGRIN3B | |
| SCHEMBL11552287 | 0.77 | PDE3A (0.46) | PDE4APDE4BPDE4CPDE4DPDE3A | |
| SCHEMBL2308673 | 0.77 | DYRK1A (0.59) | PDE4BKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL2305371 | 0.77 | DYRK1A (0.59) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL17683153 | 0.77 | ADORA2A (0.50) | PDE3APDE3BKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL30459758 | 0.77 | ADORA2A (0.50) | PDE3APDE3BKDM4ESMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382290-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250270220-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12304915-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-05-20 | — | — | US | disclosed |
| EP-4543450-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119546304-A | Salts of SOS1 inhibitors | 米拉蒂治疗公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20250059182-A1 | SOS1 INHIBITORS | MIRATI THERAPEUTICS, INC | 2025-02-20 | — | — | US | disclosed |
| CN-119462626-A | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-115135315-B | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| EP-4358963-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2023250165-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230137886-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20230137886-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| WO-2023280317-A1 | BENZYLAMINO TRICYCLIC COMPOUND AND USE THEREOF | 南京明德新药研发有限公司 | 2023-01-12 | — | — | WO | disclosed |
| WO-2022271679-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-4076418-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115135315-A | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20210188857-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
| US-20210188857-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
| WO-2021127429-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-4134980-A | Phenylalkylamino-alkyl derivatives of quinazolinone and phthalazinone | BOEHRINGER INGELHEIM GMBH (DE) | 1979-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382290-A1 | SALTS OF SOS1 INHIBITORS | SOS1, SOS2, SOST | PDE4A 3380/4885PDE4B 2919/4885PDE4C 3224/4885 |
| US-12304915-B2 | SOS1 inhibitors | SOS1, SOS2, SAV1 | PDE4A 3403/4885PDE4B 3016/4885PDE4C 3273/4885 |
| US-20250059182-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | PDE4A 2453/4885PDE4B 2015/4885PDE4C 2243/4885 |
| US-20230137886-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | PDE4A 3403/4885PDE4B 3016/4885PDE4C 3273/4885 |
| US-20250270220-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | PDE4A 3403/4885PDE4B 3016/4885PDE4C 3273/4885 |
| US-20210188857-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | PDE4A 2453/4885PDE4B 2015/4885PDE4C 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.